When the average tumor volume reached 150–200 mm3, treatments were administered as follows: the control group received intraperitoneal saline; the DDP group received intraperitoneal cisplatin (5 mg/kg) (Cao et al. 2021; Zhao et al. 2023); and the STING agonist + RG3 + DDP group received intraperitoneal RG3, STING agonist, and cisplatin. This evidence concerns the gene STING1 and neoplasm.